Evolus Balance Sheet Health

Financial Health criteria checks 2/6

Evolus has a total shareholder equity of $5.9M and total debt of $121.2M, which brings its debt-to-equity ratio to 2057.9%. Its total assets and total liabilities are $229.6M and $223.7M respectively.

Key information

2,057.9%

Debt to equity ratio

US$121.21m

Debt

Interest coverage ratio	n/a
Cash	US$85.04m
Equity	US$5.89m
Total liabilities	US$223.72m
Total assets	US$229.61m

Recent financial health updates

Recent updates

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Nov 13

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Oct 22

Evolus Continues To Make Progress

Aug 02

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Aug 02

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Jul 13

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21

Financial Position Analysis

Short Term Liabilities: EOLS's short term assets ($150.4M) exceed its short term liabilities ($60.8M).

Long Term Liabilities: EOLS's short term assets ($150.4M) do not cover its long term liabilities ($162.9M).

Debt to Equity History and Analysis

Debt Level: EOLS's net debt to equity ratio (614.1%) is considered high.

Reducing Debt: EOLS's debt to equity ratio has increased from 429.4% to 2057.9% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EOLS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EOLS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 05:40
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evolus, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Balaji Prasad	Barclays
Balaji Prasad	Barclays
Navann Ty Dietschi	BNP Paribas Exane

Evolus Balance Sheet Health

Financial Health criteria checks 2/6

Key information

Recent financial health updates

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Recent updates

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Evolus, Inc. Provides Earnings Guidance for the Year 2024

Evolus, Inc. Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

Evolus, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus Continues To Make Progress

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus, Inc. Raises Financial Guidance for the Full Year of 2024

Evolus, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus, Inc. Appoints Albert G. White III to its Board of Directors and Compensation Committee

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

Evolus: Chiseling Away At The Aesthetic Market

President recently sold US$204k worth of stock

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024

Evolus, Inc. to Report Q1, 2024 Results on May 07, 2024

Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau

Evolus, Inc. Announces Board Changes

President recently sold US$1.3m worth of stock

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Evolus, Inc. has completed a Follow-on Equity Offering in the amount of $50.00478 million.

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Price target increased by 7.6% to US$22.29

Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024

Evolus, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Independent Director notifies of intention to sell stock

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Evolus, Inc. Announces Earnings Guidance for 2024

Evolus, Inc. Appoints Nareg Sagherian as Head of Global Investor Relations and Corporate Communications

New minor risk - Shareholder dilution

President recently sold US$822k worth of stock

President notifies of intention to sell stock

New minor risk - Insider selling

No longer forecast to breakeven

Evolus, Inc. Raises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$20.25

Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau

Evolus, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Evolus, Inc. Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

President recently sold US$152k worth of stock

Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Evolus, Inc. Revises Revenue Guidance for the Year 2023

Evolus Launches Nuceiva (Botulinum Toxin Type A) in Italy

Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau (R)

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Price target increased by 9.4% to US$18.11

Consensus EPS estimates fall by 46%

Price target increased by 8.4% to US$17.22

Evolus, Inc. Provides Revenue Guidance for the Year 2023

Evolus, Inc. to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings: EPS misses analyst expectations

Evolus, Inc. Announces "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase Ii Data Results, Representing Prolonged 6-Month Performance

Evolus, Inc. Receives Regulatory Approval for Nuceiva® in Australia

Evolus, Inc. Provides Earnings Guidance for the Year 2023

Forecast to breakeven in 2025

Insufficient new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Evolus, Inc. Provides Earnings Guidance for the Full Year 2022

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Evolus concludes certain royalty payments related to settlement of IP rights dispute